Literature DB >> 32286721

The future of translational research on alcohol use disorder.

Lara A Ray1, Erica N Grodin1, Lorenzo Leggio2, Anita J Bechtholt3, Howard Becker4, Sarah W Feldstein Ewing5, James David Jentsch6, Andrea C King7, Barbara J Mason8, Stephanie O'Malley9, James MacKillop10, Markus Heilig11, George F Koob12.   

Abstract

In March 2019, a scientific meeting was held at the University of California, Los Angeles (UCLA) Luskin Center to discuss approaches to expedite the translation of neurobiological insights to advances in the treatment of alcohol use disorder (AUD). A guiding theme that emerged was that while translational research in AUD is clearly a challenge, it is also a field ripe with opportunities. Herein, we seek to summarize and disseminate the recommendations for the future of translational AUD research using four sections. First, we briefly review the current landscape of AUD treatment including the available evidence-based treatments and their uptake in clinical settings. Second, we discuss AUD treatment development efforts from a translational science viewpoint. We review current hurdles to treatment development as well as opportunities for mechanism-informed treatment. Third, we consider models of translational science and public health impact. Together, these critical insights serve as the bases for a series of recommendations and future directions. Towards the goal of improving clinical care and population health for AUD, scientists are tasked with bolstering the clinical applicability of their research findings so as to expedite the translation of knowledge into patient care.
© 2020 Society for the Study of Addiction.

Entities:  

Keywords:  AUD; medications; research; translational; treatment; treatment gap

Mesh:

Substances:

Year:  2020        PMID: 32286721      PMCID: PMC7554164          DOI: 10.1111/adb.12903

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  90 in total

1.  Striatal D1- and D2-type dopamine receptors are linked to motor response inhibition in human subjects.

Authors:  Chelsea L Robertson; Kenji Ishibashi; Mark A Mandelkern; Amira K Brown; Dara G Ghahremani; Fred Sabb; Robert Bilder; Tyrone Cannon; Jacqueline Borg; Edythe D London
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 2.  Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safety.

Authors:  Raye Z Litten; Bonnie B Wilford; Daniel E Falk; Megan L Ryan; Joanne B Fertig
Journal:  Subst Abus       Date:  2016 Apr-Jun       Impact factor: 3.716

3.  Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging.

Authors:  Karl Mann; Sabine Vollstädt-Klein; Iris Reinhard; Tagrid Leménager; Mira Fauth-Bühler; Derik Hermann; Sabine Hoffmann; Ulrich S Zimmermann; Falk Kiefer; Andreas Heinz; Michael N Smolka
Journal:  Alcohol Clin Exp Res       Date:  2014-11       Impact factor: 3.455

4.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.

Authors:  Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

5.  Differences Between Treatment-Seeking and Nontreatment-Seeking Alcohol-Dependent Research Participants: An Exploratory Analysis.

Authors:  Matthew C H Rohn; Mary R Lee; Samuel B Kleuter; Melanie L Schwandt; Daniel E Falk; Lorenzo Leggio
Journal:  Alcohol Clin Exp Res       Date:  2017-02       Impact factor: 3.455

6.  Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population.

Authors:  Deborah S Hasin; Melanie Wall; Katie Witkiewitz; Henry R Kranzler; Daniel Falk; Raye Litten; Karl Mann; Stephanie S O'Malley; Jennifer Scodes; Rebecca L Robinson; Raymond Anton
Journal:  Lancet Psychiatry       Date:  2017-04-26       Impact factor: 27.083

7.  Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials.

Authors:  Molly Magill; Lara A Ray
Journal:  J Stud Alcohol Drugs       Date:  2009-07       Impact factor: 2.582

Review 8.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

Review 9.  Cognitive behavioral interventions for alcohol and drug use disorders: Through the stage model and back again.

Authors:  Kathleen M Carroll; Brian D Kiluk
Journal:  Psychol Addict Behav       Date:  2017-08-31

10.  Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations.

Authors:  Henry R Kranzler; Hang Zhou; Rachel L Kember; Rachel Vickers Smith; Amy C Justice; Scott Damrauer; Philip S Tsao; Derek Klarin; Aris Baras; Jeffrey Reid; John Overton; Daniel J Rader; Zhongshan Cheng; Janet P Tate; William C Becker; John Concato; Ke Xu; Renato Polimanti; Hongyu Zhao; Joel Gelernter
Journal:  Nat Commun       Date:  2019-04-02       Impact factor: 14.919

View more
  8 in total

1.  The Etiologic, Theory-Based, Ontogenetic Hierarchical Framework of Alcohol Use Disorder: A Translational Systematic Review of Reviews.

Authors:  Cassandra L Boness; Ashley L Watts; Kimberly N Moeller; Kenneth J Sher
Journal:  Psychol Bull       Date:  2021-10       Impact factor: 17.737

2.  Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.

Authors:  Lara A Ray; ReJoyce Green; Craig Enders; Adam M Leventhal; Erica N Grodin; Gang Li; Aaron Lim; Emily Hartwell; Alex Venegas; Lindsay Meredith; Steven J Nieto; Steven Shoptaw; Diana Ho; Karen Miotto
Journal:  Am J Psychiatry       Date:  2021-06-03       Impact factor: 19.242

3.  Reward drinking and naltrexone treatment response among young adult heavy drinkers.

Authors:  Corey R Roos; Krysten W Bold; Katie Witkiewitz; Robert F Leeman; Kelly S DeMartini; Lisa M Fucito; William R Corbin; Karl Mann; Henry R Kranzler; Stephanie S O'Malley
Journal:  Addiction       Date:  2021-03-18       Impact factor: 7.256

4.  Differential association between the GLP1R gene variants and brain functional connectivity according to the severity of alcohol use.

Authors:  Mehdi Farokhnia; Samantha J Fede; Erica N Grodin; Brittney D Browning; Madeline E Crozier; Melanie L Schwandt; Colin A Hodgkinson; Reza Momenan; Lorenzo Leggio
Journal:  Sci Rep       Date:  2022-07-29       Impact factor: 4.996

Review 5.  A meta-regression of methodological features that predict the effects of medications on the subjective response to alcohol.

Authors:  ReJoyce Green; Han Du; Erica N Grodin; Steven J Nieto; Spencer Bujarski; Daniel J O Roche; Lara A Ray
Journal:  Alcohol Clin Exp Res       Date:  2021-07-05       Impact factor: 3.928

6.  Drinking reduction during cognitive behavioral therapy for alcohol use disorder is associated with a reduction in anterior insula-bed nucleus of the stria terminalis resting-state functional connectivity.

Authors:  A Benjamin Srivastava; Juan Sanchez-Peña; Frances R Levin; John J Mariani; Gaurav H Patel; Nasir H Naqvi
Journal:  Alcohol Clin Exp Res       Date:  2021-08-02       Impact factor: 3.928

Review 7.  Immune treatments for alcohol use disorder: A translational framework.

Authors:  Lindsay R Meredith; Elizabeth M Burnette; Erica N Grodin; Michael R Irwin; Lara A Ray
Journal:  Brain Behav Immun       Date:  2021-07-31       Impact factor: 19.227

Review 8.  A Critical Review of Alcohol Administration Guidelines in Laboratory Medication Screening Research: Is It Time to Include Treatment Seekers?

Authors:  Walter Roberts; Terril L Verplaetse; Vijay A Ramchandani; Sherry A McKee
Journal:  Alcohol Clin Exp Res       Date:  2020-12-20       Impact factor: 3.928

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.